• 1. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 2. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 3. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 4. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 5. Excimer–monomer switch: a reaction-based approach for selective detection of fluoride?
  Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidones
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives Pyrimidones

Introduction to 6-Amino-1,3-dibutyluracil (CAS No. 41862-16-2)

6-Amino-1,3-dibutyluracil, identified by the Chemical Abstracts Service Number (CAS No.) 41862-16-2, is a significant compound in the field of pharmaceutical chemistry and bioorganic synthesis. This heterocyclic organic molecule, characterized by its uracil backbone with amino and butyl substituents, has garnered attention due to its versatile applications in medicinal chemistry and potential roles in drug development. The structural features of 6-Amino-1,3-dibutyluracil make it a valuable intermediate in the synthesis of more complex molecules, particularly those targeting neurological and inflammatory pathways.

The chemical structure of 6-Amino-1,3-dibutyluracil consists of a pyrimidine ring system with amino groups at the 6th position and butyl groups at the 1st and 3rd positions. This arrangement imparts unique electronic and steric properties to the molecule, influencing its reactivity and biological interactions. The presence of the amino group enhances its potential as a nucleophile in various synthetic transformations, while the butyl substituents contribute to lipophilicity, which can be crucial for membrane permeability and bioavailability in drug formulations.

In recent years, 6-Amino-1,3-dibutyluracil has been explored in the context of developing novel therapeutic agents. One of the most promising areas is its application in the synthesis of kinase inhibitors, which are pivotal in treating cancers and inflammatory diseases. The uracil core is a common scaffold in many biologically active compounds, and modifications at specific positions can lead to enhanced potency and selectivity. For instance, studies have demonstrated that derivatives of 6-Amino-1,3-dibutyluracil can interact with ATP-binding sites on kinases, thereby modulating their activity.

Moreover, research has highlighted the role of 6-Amino-1,3-dibutyluracil in developing antiviral agents. The structural similarity between uracil derivatives and natural nucleobases allows these compounds to interfere with viral replication processes. Specifically, they can compete with natural nucleotides during DNA/RNA synthesis or inhibit viral polymerases. Preliminary studies have shown that certain modifications of 6-Amino-1,3-dibutyluracil can lead to compounds with significant antiviral activity against RNA viruses, including those responsible for respiratory infections.

The synthesis of 6-Amino-1,3-dibutyluracil typically involves multi-step organic reactions starting from commercially available precursors. One common approach includes the condensation of urea derivatives with β-ketoesters followed by functional group transformations to introduce the amino and butyl groups at desired positions. Advances in synthetic methodologies have enabled more efficient and scalable production processes for this compound, making it more accessible for research applications.

From a computational chemistry perspective, 6-Amino-1,3-dibutyluracil has been subjected to extensive molecular modeling studies to understand its interactions with biological targets. Quantum mechanical calculations have provided insights into its binding affinities and mode of action at various receptors. These computational insights are invaluable for designing next-generation drugs that are both potent and selective.

The pharmacokinetic properties of 6-Amino-1,3-dibutyluracil are also subjects of interest. Studies have evaluated its solubility, stability under physiological conditions, and metabolic pathways. Understanding these parameters is crucial for optimizing drug formulations and ensuring therapeutic efficacy. For example, modifications aimed at improving solubility can enhance oral bioavailability while reducing toxicity.

In conclusion,6-Amino-1,3-dibutyluracil (CAS No. 41862-16-2) represents a fascinating compound with broad applications in pharmaceutical research. Its unique structural features make it a versatile building block for drug discovery efforts targeting various diseases. As research continues to uncover new biological functions and synthetic strategies,6-Amino-1,3-dibutyluracil is poised to play an increasingly important role in developing innovative therapeutic solutions.

• 41862-14-0(6-Amino-1,3-dipropyluracil)
• 550-28-7(Amisometradine)
• 53681-47-3(6-amino-1-propyl-1,2,3,4-tetrahydropyrimidine-2,4-dione)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)